CAS 3569-10-6 Valerenic acid - Analytical Products / Alfa Chemistry

CAT	AP3569106
CAS	3569-10-6
Structure
MDL Number	MFCD00075694
Molecular Weight	234.33
InChI Key	FEBNTWHYQKGEIQ-SUKRRCERSA-N
REAXYS Number	3138020

"Effect of Valerenic Acid on Neuroinflammation in a MPTP-induced Mouse Model of Parkinson's Disease"

Alfredo Rodríguez-Cruz, Antonio Romo-Mancillas, Jesus Mendiola-Precoma, Jesica Esther Escobar-Cabrera, Guadalupe García-Alcocer, Laura Cristina Berumen

IBRO Rep. 2019 Dec 17;8:28-35.

PMID: 31909290

The Anxiolytic Effects of a Valerian Extract Is Based on Valerenic Acid

Axel Becker, Falko Felgentreff, Helmut Schröder, Beat Meier, Axel Brattström

BMC Complement Altern Med. 2014 Jul 28;14:267.

PMID: 25066015

The Roles of Valerenic Acid on BDNF Expression in the SH-SY5Y Cell

Ekrem-Murat Gonulalan, Omer Bayazeid, Funda-Nuray Yalcin, Lutfiye-Omur Demirezer

Saudi Pharm J. 2018 Nov;26(7):960-964.

PMID: 30416353

Valerian

PMID: 30000874

Valerian Extract Characterized by High Valerenic Acid and Low Acetoxy Valerenic Acid Contents Demonstrates Anxiolytic Activity

F Felgentreff, A Becker, B Meier, A Brattström

Phytomedicine. 2012 Oct 15;19(13):1216-22.

PMID: 22944521

* Products or Services Interested: Valerenic acid (3569-10-6)
* Your question
* Name
* Email
Verification Code

Case Study

Valerenic Acid Induces Cytotoxicity in Glioblastoma Multiforme Cells by Targeting HTR5A and Activating AMPK

Lu, Qingli, Yuan Ding, and Yang Li. International Journal of Biological Sciences 16.12 (2020): 2104.

Glioblastoma multiforme (GBM) continues to threaten lives due to limited therapeutic strategies. As a new drug, valerenic acid can suppress the progression of GBM, but its mechanism remains unclear.
In this study, we found that one of the 5-HT receptors, HTR5A, was downregulated in high-grade GBM compared to low-grade glioma. Valerenic acid, a potential agonist of HTR5A, exhibited strong cytotoxic effects in GBM cells by inhibiting cell proliferation, EMT, migration, and invasion. Mechanistically, ROS induction and AMPK activation were responsible for valerenic acid-induced cell death in GBM cells. The anti-tumor effects of valerenic acid were also validated in an in vivo xenograft GBM mouse model.
In conclusion, valerenic acid may be a potential anti-tumor agent for GBM patients.

Therapeutic Mechanism of Valerenic Acid (VA) in Pathological Myocardial Hypertrophy (PMH)

Liu, Tiantian, et al. Journal of Advanced Research (2024).

Valerenic acid (VA) is a unique bioactive component found in valerian, and it has been reported to have regulatory effects on the cardiovascular system. However, its therapeutic effects on pathological myocardial hypertrophy (PMH) and the underlying mechanisms are not yet clear.
VA enhances fatty acid oxidation (FAO) in cardiomyocytes, suppresses overactivated glycolysis, and improves the imbalanced pyruvate-lactate axis. VA significantly improves impaired mitochondrial function, reduces triglyceride (TG) levels in hypertrophic myocardium, and decreases lactate (LD) content. Molecular mechanism studies indicate that VA upregulates the expression of peroxisome proliferator-activated receptor alpha (PPARα) and downstream FAO-related genes, including CD36, CPT1A, EHHADH, and MCAD. VA reduces the expression of key enzymes in glycolysis such as ENO1 and PDK4. Additionally, VA improves the pyruvate-lactate axis and promotes aerobic oxidation of pyruvate by inhibiting LDAH and MCT4. Molecular dynamics simulations confirmed that VA can bind to the F273 site of PPARα, suggesting that VA is a potential PPARα activator.
The study results suggest that VA may be a potent activator of the PPARα-mediated pathway. By directly targeting PPARα and subsequently promoting energy metabolism, VA alleviates PMH and may serve as a potentially effective drug for the treatment of heart failure (HF).